SEC Form SC 13G/A filed by Sangamo Therapeutics Inc. (Amendment)
$SGMO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/7/2025 | $1.00 | Overweight → Equal Weight | Barclays |
| 12/13/2024 | $7.00 | Hold → Buy | Truist |
| 12/10/2024 | $10.00 | Buy | H.C. Wainwright |
| 11/3/2023 | $6.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 4/28/2023 | $5.00 → $1.50 | Neutral → Underperform | BofA Securities |
| 2/27/2023 | $16.00 | Neutral → Outperform | Wedbush |
| 1/6/2023 | $8.00 → $5.00 | Buy → Neutral | BofA Securities |
| 6/13/2022 | $5.00 | Neutral | Wedbush |
10-Q - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Presented detailed clinical data from registrational STAAR study showing potential for isaralgagene civaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care. Patient recruitment and enrollment in progress for Phase 1/2 STAND study in chronic neuropathic pain following activation of two clinical si
RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. The company will hold a conference call at 8:30 a.m. Eastern on Thursday, November 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants wil
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval Isaralgagene civaparvovec showed a favorable safety and tolerability profile Sangamo intends to submit a Biologics License Application (BLA) in 2026 under the Accelerated Approval pathway RICHMOND, Calif., Sept. 04,
Barclays downgraded Sangamo Therapeutics from Overweight to Equal Weight and set a new price target of $1.00
Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00
H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm
CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa
Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated approval pathway for isaralgagene civaparvovec in Fabry disease. Presented detailed clinical data from registrational STAAR study showing potential for isaralgagene civaparvovec as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care. Patient recruitment and enrollment in progress for Phase 1/2 STAND study in chronic neuropathic pain following activation of two clinical si
RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. The company will hold a conference call at 8:30 a.m. Eastern on Thursday, November 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants wil
Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain. Expect to dose first patient in fall of 2025, with preliminary proof of efficacy data anticipated in late 2026. Held productive meeting with Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study ahead of anticipated Clinical Trial Application (CTA) submissi